Kornimate/medical-research-clean huggingface dataset:
the effect of telephone consulting on hba1 and self-management

Conditions: Type 2 Diabetes; Self-management

Summary: the aim of this study was to investigate the effect of telephone counseling (12 weeks) based on the information, motivation, behavioral skills (imb) model in patients with type 2 diabetes mellitus (t2dm) on self-management and hba1c.

the aim of this study was to investigate the effect of telephone counseling based on the information, motivation, behavioral skills (imb) model in patients with type 2 diabetes mellitus (t2dm) on self-management and hba1c. this study was conducted with a randomized controlled trial. this study, between january 2019 and september 2019 were conducted in endocrine clinic. a total of 63 patients (31 interventions, 32 controls) diagnosed with t2dm were included. the intervention group received 45-60 minutes of patient training based on the information, motivation and behavioral skill model (imb). a weekly short reminder message and a two-weekly phone call were made and a total of 12 weeks of follow-up was conducted. as a result, there was a statistically significant difference between pre-test hba1c, weight and systolic blood pressure (p\<0.05). also, after three months of follow-up, self-efficacy, self-management and self-management perceptions were significantly higher in the intervention group (p\<0.05).

Eligibility criteria:
inclusion criteria: * diagnosis with type 2 dm at least six months previously * using a mobile phone * hba1c greater than 7% * living in the city * physical and mental health levels adequate for participation in the research exclusion criteria: * having severe hearing or perceptual deficits that impaired communication * patients who did not agree to participate in the study * receiving inpatient treatment

Keywords: type 2 diabetes telephone counseling imb self-management hba1c
motexafin gadolinium with chemotherapy and radiation therapy for the treatment of advanced head and neck cancer

Conditions: Head and Neck Cancer; Oropharynx Cancer; Larynx Cancer; Hypopharynx Cancer

Summary: the purpose of this study is to evaluate the safety of adding the investigational drug motexafin gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-fu and cisplatin in patients with advanced head and neck cancer.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * each patient must sign a study-specific informed consent form * newly diagnosed, locally advanced, non-metastatic squamous cell carcinoma of the head and neck (scchn) arising from a primary site in the oropharynx, hypopharynx, or larynx confirmed by evaluation of fine needle aspiration or biopsy samples and mri * eligible for curative intent treatment with hyperfractionated radiation and concurrent 5-fu and cisplatin * karnofsky performance status score of at least 60% * primary tumor at least 4 cm in diameter exclusion criteria: laboratory values of: * serum creatinine \> 1.8 mg/dl; unless 24-hour urine creatinine clearance is ≥ 70 ml/min * serum total bilirubin \> 1.5 times the upper limit of normal * alt (formerly sgpt) \> 1.5 times the upper limit of normal * alkaline phosphatase \> 1.5 times the upper limit of normal * absolute neutrophil count (anc) \< 1500/l * platelet count \< 100,000/l * 3+ or greater proteinuria on urinalysis and * squamous cell carcinoma of the head and neck arising from a primary site in the oral cavity or nasopharynx * distant metastases * prior history of cancer at any site treated with radiotherapy and/or chemotherapy * history of scchn diagnosed within 5 years of current diagnosis

Keywords: head and neck cancer scchn oropharynx cancer hypopharynx cancer larynx cancer soft palate cancer tonsil cancer base of tongue cancer supraglottic cancer glottic cancer pyriform sinus cancer pharyngeal wall cancer throat cancer
chlamydia and mycoplasma in coronary artery disease

Conditions: Atherosclerosis; Coronary Artery Disease; Chlamydia Infections; Mycoplasma Infections

Summary: to test the association between anti-chlamydia serum titers and anti-mycoplasma antibodies with acute coronary syndromes.

one hundred and twenty-six patients were divided into 4 groups: acute coronary syndrome with st-elevation, non-st-elevation, stable coronary artery disease, and individuals without coronary disease. anti-chlamydia and anti-mycoplasma igg antibodies were measured at baseline and after 6 months.

Eligibility criteria:
inclusion criteria: * age \>18 yrs * males and females * agreed to sign the informed consent exclusion criteria: * refusal to sign the informed consent * follow-up not possible * for the "acute" groups, time between the pain beginning and randomization \>24 hours * active infections * use of antimicrobial agents within the last 30 days * end-stage diseases with life expectancy \<6 months

Keywords: atherosclerosis coronary artery disease chlamydia pneumoniae mycoplasma pneumoniae
angelman & rett syndrome: interaction and communication

Conditions: Behavior, Child; Parent-Child Relations; Communication

Summary: we aim to describe the communicative and sensory profile of children with angelman syndrome or rett syndrome and their use of augmentative and alternative communication. in addition, parents are surveyed regarding parent-child interaction and access to communication support.


Eligibility criteria:
inclusion criteria: * angelman or rett syndrome exclusion criteria: * none
effects of a pre-school-based nutritional intervention on children's eating behavior and anthropometric parameters

Conditions: Obesity

Summary: this study assesses the impact of a nutritional intervention aimed at reducing childhood overweight in german preschoolers.

objective: to assess the impact of a nutritional intervention aimed at reducing childhood overweight in german preschoolers. design: using a cluster-randomized study design with waiting-list controls, we test a six-month intervention administered once weekly by a nutritional expert consisting of joint meal preparation and activities for children and parents like tasting and preparing nutritious, fresh foods. at baseline, six and twelve months, a parent-completed questionnaire assesses fruit and vegetable intake (primary outcomes) and water and sugared drink consumption (other outcomes). direct measurement assessed bmi, percentage body fat (skin fold thicknesses) and waist-to-height-ratio. an intention-to-treat analysis used random effects panel regression models to assess the intervention effect, adjusted for each child's age, gender, immigrant background and maternal education. setting: 18 preschools from three south german regions. subjects: healthy children from three to seven years of age.

Eligibility criteria:
inclusion criteria: * pre-schools were eligible to participate in the study if they were located in one of three predefined regions and had applied to participate in the nutritional intervention module of a state-sponsored health promotion programme 'komm mit in das gesunde boot' ('come aboard the health boat'), with at least fifteen children participating. * healthy children in eligible preschools exclusion criteria: * age under 3 years or above 7 years * serious health problems * genetic conditions * metabolic diseases * acute infectious diseases
pattern of use and safety/effectiveness of nivolumab in routine oncology practice

Conditions: Melanoma; Lung Cancer

Summary: this is an observational, multicenter study in participants treated with nivolumab for the approved indications of melanoma and lung cancer in australia, the eu, switzerland, the united kingdom (uk), and the united states (us). the targeted countries in the eu for study participation include austria, belgium, czech republic, france, germany, hungary, italy, poland, and spain. study objectives are to assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab in routine oncology care facilities.


Eligibility criteria:
inclusion criteria: * age ≥18 * histologically or cytologically confirmed diagnosis of melanoma (including uveal melanoma) or lung cancer * treatment with commercial nivolumab for the first time, alone or in combination with ipilimumab, for the approved indications of nivolumab within 14 days before informed consent for this study or in the case where treatment has not yet been initiated, documentation that the treatment strategy is determined before an informed consent to study participation, and treatment is initiated within 28 days after informed consent exclusion criteria: * prior participation in a clinical trial within the past 4 weeks * previously treated with anti-pd-1, anti-pd-l1, or anti-pd-l2 antibodies * previously treated with anti-ctla-4 for lung cancer * current or pending participation in a clinical trial * current or pending systemic treatment for cancer other than melanoma and lung cancer * inability to comply with the study protocol
evaluation of the effectiveness of a protocol for the management of female functional urinary signs

Conditions: Cystitis Acute

Summary: every year, between 4 and 6 million french people are affected by a urinary infection; the vast majority of these are women. although the diagnosis of an uncomplicated urinary tract infection is simple to make, it requires prompt medical management to relieve the symptoms. the lack of immediate of a physician can slow down the management of patients affected by this condition, and lead to an inappropriate referral of patients to the emergency services. because of their wide availability, accessibility, and geographical distribution throughout the country, pharmacists are primary health care professionals who are regularly called upon to respond to patients with this type of infection. a national protocol exists in france, but it is very difficult to apply. the pharmacyst' study aims to evaluate its application in community pharmacies.


Eligibility criteria:
inclusion criteria: * female * age ≥ 18 and \<65 years * patient with less than 3 days of simple urinary tract infection symptoms: * burning, pain on urination * dysuria * pollakiuria * urinary urgency * patient affiliated or beneficiary of a social insurance * patient having signed an informed consent. exclusion criteria: * more than 3 cystitis in the last 12 months; * last cystitis less than 15 days old; * presence of fever; * presence of back pain; * presence of a functional or organic anomaly of the urinary tract (bladder residue, vesico-ureteral reflux, lithiasis, tumor); * pruritus or vaginal discharge; * vomiting, diarrhea, diffuse abdominal pain; * risk factors for c3g-resistant enterobacteria infection (grade b): * exposure to an antibiotic (amoxicillin-clavulanic acid, c2g, c3g, fluoroquinolones) within the previous 3 months; * a nosocomial or healthcare-associated infection; * a history of colonization or infection with c3g-resistant enterobacteria within the last 3 months; * a trip to a foreign country within the last 3 months in known geographical areas at risk (in particular the indian subcontinent, south-east asia, the middle east and north africa, the mediterranean basin); * hospitalization within 3 months; * hospitalization within 6 months for uti; * known severe renal insufficiency (creatinine clearance \< 30 ml/min); * severe immunosuppression or immunosuppressive treatments; * contraindications to drugs planned for experimental management (pivmecillinam and fosfomycin) or combination of drugs not recommended; * pregnant women (confirmed or suspected pregnancy), breastfeeding women or women in labour; * person deprived of liberty by judicial or administrative decision; * person under forced psychiatric care; * person admitted to a health or social institution for purposes other than research; * person subject to a legal protection measure; * a person who is unable to give consent.
perturbation based neuromuscular training effects on peroneal strength, fatigue and functional performance parameters

Conditions: Healthy Young Women; Basketball Players

Summary: in the literature neuromuscular exercise programs are often used for prevention in sport players. literature lacks of perturbation exercises and its effects on peroneal's muscle strength, fatigue and individual's performance parameters. this study will investigate if it is possible to achieve improvements on peroneal eccentric strength, fatigue, dynamic balance and individual's performance with the exercises mainly based on side perturbations.

chronic ankle instability is very common in adolescent female basketball players. in the literature neuromuscular exercise programs are often used for prevention in sport players that usually contains of strength and/or balance exercises. perturbation exercises are oftenly used in sport players for returning the sport or prevention but literature lacks of its effects statistically. this study will investigate if it is possible to achieve improvements on peroneal eccentric strength, fatigue, dynamic balance and individual's performance with the exercises mainly based on side perturbations. strength and fatigue evaluations will be made with cybex dynanometer. dynamic balance evaluations will be made with y-balance tests. individual's performance parameter evaluations will be made with vertical jump test, cross jump test and side hop test.

Eligibility criteria:
inclusion criteria: * healthy, non-injured within the 6 months female basketball players that are willing to join the research exclusion criteria: * that has a injury within 6 months with missing trainings at least 2 times in a row or having vestibuler dysfunction
exploratory study in the relief of drug-induced xerostomia associated with hyposialia

Conditions: Drug-induced Xerostomia

Summary: the purpose of this study is to evaluate the clinical efficacy, the safety and acceptability of three new oral sprays with a reference oral spray in the relief of drug-induced xerostomia associated with hyposialia, i.e. dryness of the mouth induced by a decrease of salivation (hyposialia) induced by chronic drug intake.


Eligibility criteria:
inclusion criteria: * male and female subjects, * adult subjects (≥18 years) taking drug(s) causing salivary hypofunction / xerostomia, for at least 1 week prior to study initiation and expected to continue without change during study * subjects with a complaint of dry mouth as assessed by a response of 40mm or greater on item "rate the dryness of your mouth" of the dry mouth visual analogue scale (vas) questions. (the vas limits will be 0 representing normal \[i.e. no dry mouth symptoms\] and 100 representing "the worst imaginable" dry mouth symptoms). this score should also be met before the 1st product application, on p1 d1. * documented hyposalivation with test of resting saliva weight absorbed ≤ 0.5g/5 min at baseline exclusion criteria: * presence of disorders (bucco-dental disease, history of major medical/psychiatric illness or surgery, ... ) which, in the judgement of the investigator, may interfere with study implementation and/or study parameter assessment(s). * sjögren syndrome and related autoimmune diseases, * other medical causes of xerostomia (oral candidiasis). * history of head and neck irradiation and cancer chemotherapy * history of hypersensitivity to any of the components of the investigational products, * history or current excessive use of alcohol, * history of drug addiction, * presence of treatments for their dry mouth within 7 days prior to inclusion into the study

Keywords: xerostomia hyposialia hyposalivation saliva substitute salivary gland mouth diseases dry mouth
adrenaline reduces ecchymoses and hematomas and improves quality of life after classic saphenous vein stripping

Conditions: Venous Insufficiency (Chronic)(Peripheral); Venous Reflux; Venous Insufficiency of Leg; Venous Stasis; Venous Disease; Subcutaneous Haematoma; Ecchymosis; Bruising

Summary: aim of the present study is to investigate the efficiency of adrenaline (epinephrine) used locally in reducing and avoiding post-operative formation of subcutaneous ecchymoses and hematomas, in comparison with traditional practice of hemostasis, and to assess improvement in the quality of life of subjects undergoing classic great saphenous vein stripping, who received or did not receive adrenaline as a local hemostatic.

introduction quality of life of subjects undergoing classic great saphenous vein stripping is analogous of the gravity of subcutaneous ecchymoses and hematomas formation, as a result of surgical interventions during open surgery, when the great saphenous vein is being removed. adrenaline (epinephrine) is a potent vasoconstrictor, whose local hemostatic ability has already been documented and applied in many medical specialties. aim of the present study to investigate the efficiency of adrenaline (epinephrine) used locally in reducing and avoiding post-operative formation of subcutaneous ecchymoses and hematomas, in comparison with traditional practice of hemostasis, and to assess improvement in the quality of life of subjects undergoing classic great saphenous vein stripping, who received or did not receive adrenaline as a local hemostatic. material-methods 40 subjects diagnosed with chronic venous insufficiency (cvi) and/or varicose veins of the lower limbs of varied clinical gravity (ceap classification ii \& iii), admitted in the department of vascular surgery for open surgical management, i.e. great saphenous vein stripping +/- removal of varicosities, will be enrolled after signing an informed consent for their participation in the study. they will be then randomized into 3 separate groups: group a - great saphenous vein stripping with local adrenaline use for hemostasis group b - great saphenous vein stripping with local normal saline use for hemostasis group c - great saphenous vein stripping with traditional hemostatic practice study subjects will be followed-up after surgery, and in each group measurement of ecchymoses (small 2-5mm2 and large \>5mm2) and hematomas (medium 0,2-1cm and large \>1cm) will be performed by using imagej software after digital high-resolution photographing on 1st, 8th and 14th post-operative days. quality of life of subjects will be assessed pre-operatively and 1 month post-operatively, by using sf-36 and civiq-2 questionnaires for qol in cvi.

Eligibility criteria:
inclusion criteria: * age 18-80 years * cvi ceap class ii or iii * informed consent signed exclusion criteria: * age \ 80 years * cvi ceap class i or iv (venous ulcers) * allergy to adrenaline history * no informed consent signed

Keywords: great saphenous vein saphenectomy saphenous vein stripping ecchymosis haematoma adrenaline epinephrin hemostasis chronic venous insufficiency venous reflux venous disease
genetesis accelerated registry

Conditions: Acute Myocardial Infarction; Acute Coronary Syndrome

Summary: heart disease is the number one cause of death in the united states, with over 650,000 deaths in 2019 alone. many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. the purpose of the genetesis accelerated registry (gear) study is to understand the potential for magnetocardiography to be utilized as a diagnostic, screening or surveillance tool for heart disease in healthy and non-healthy volunteers. magnetocardiography (mcg) is a diagnostic method that analyzes and records the magnetic fields of the heart for the detection of various forms of heart disease. there will be a 12-month duration of the study where we propose to collect screening data from approximately 500 volunteers who present to the genetesis facility for a 5-minute cardioflux mcg scan. the volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age at the time of enrollment. exclusion criteria: 1. \< 18 years of age 2. patients unable to fit into device 3. non-ambulatory patients 4. patients with present with or have reasonable clinical suspicion of any acute coronary syndrome for which delayed intervention could increase the risk or magnitude of damaged myocardium 5. patients with claustrophobia or unable to lie supine for 5 minutes 6. pregnant women 7. poor candidate for follow-up (e.g. no access to phone) 8. prisoners 9. patients with a language barrier/language difficulties

Keywords: ischemia acute myocardial injuries cardioflux mcg cardiovascular disease
patient-centered pd ambulatory monitoring system

Conditions: Parkinson Disease

Summary: this a usability study of a wearable sensor platform that utilizes a smartwatch to periodically record motion data. that data is processed in a connected smartphone and translated into symptom scores for dyskinesia, slowness, and tremor. the research subjects will use the wearable system over the course of five weeks, during which a change in therapy regimen is prescribed by the physician. research analysis will be focused on patient and clinician experiences with the app and its reports.


Eligibility criteria:
inclusion criteria: * existing patient of collaborating physician (david e. riley, md) * diagnosed with parkinson's disease * hoehn \& yahr scale i-iii * ambulatory and capable of using the parkinpal system * able to understand and follow instructions regarding using the device exclusion criteria: * any subject that does not meet the subject selection criteria will be excluded from this study. children will be excluded from this study due to the fact that they are unlikely to have pd. subjects that are not capable of functioning independently or are so symptomatic as to compromise their safety will also be excluded.
determination of carboplatin's optimal plasmatic exposure

Conditions: Neoplasms

Summary: to determine carboplatin's optimal exposures(optimal aucs)and parameters they depend on.


Eligibility criteria:
inclusion criteria: * carcinoma histologically proved and which must be treated by carboplatin, excepted weekly administered carboplatin treatments * age \> 18 years * neutrophils \> 1500/mm3, blood-platelets \> 100000/mm3 * patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for investigators centers achieving pharmacokinetic examination) * well-informed written consent, signed by the patient exclusion criteria: * carboplatin treatment's contra-indication * patient with clinically detectable cerebral metastasis * pregnant or nursing women * patient under guardianship or trusteeship * patient whose venous status don't permit a peripheral intravenous administration route's placing (for investigators centers achieving pharmacokinetic examination)

Keywords: neoplasms carboplatin optimal exposure auc